Newly diagnosed PAH patients on triple therapy have fewer hospitalizations vs. double therapy

Feb 18, 2025

1 min read

A study looked at about 3000 pulmonary arterial hypertension patients and found that people who added selexipag to double therapy (an endothelin receptor agonist like ambrisentan, macitentan, or bosentan and a phosphodiesterase type 5 inhibitor like sildenafil or tadalafil) within six months had a lower risk of hospitalization and disease progression. They suggest that delaying the start of triple therapy contributes to worse outcomes.

Read the JAMA Network Open paper

Recent Posts

Patient and Clinician Views on Shared Decision-Making

Preference for shared decision-making was nearly universal among patients and clinicians. However, priorities differed significantly. Patients more frequently emphasized quality of life (81% vs. 54%)

Why lived experience must shape research

"Drawing on decades of patient advocacy, two women living with the rare condition Congenital Melanocytic Naevus argue that lived experience must shape research from the outset, and discuss how genuine

More than half of pulmonary fibrosis patients have PH

There is not much data looking at pulmonary hypertension (PH) in interstitial lung disease, except in idiopathic pulmonary fibrosis (IPF). A study of patients with pulmonary fibrosis found that 60.7%

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.